Table 2.

Effects of zoledronic acid versus placebo on skeletal-related events (SREs) in patients with renal cell carcinoma or bladder cancer.

Endpoint	Renal cell carcinoma [Abrahamsson et al. 2008; Lipton et al. 2003; Saad and Lipton, 2005]	Bladder cancer [Zaghloul et al. 2010]
Reduced proportion of patients with ≥1 SRE	41% versus 79%; p=0.011	65% versus 90%; p=0.010
Reduced mean number of SREs	NR	0.95 versus 2.05; p=0.001
Prolonged median time to first SRE	424 versus 72 days; p=0.007	112 versus 56 days; p=0.0001
Reduced skeletal morbidity rate	2.58 versus 3.13; p=0.009	NR
Reduced risk of developing an SRE	58% (HR=0.418; p=0.010)	50% (HR=0.413; p=0.008)
Delayed time to first pathologic fracture	Not reached versus 168 days; p=0.003	NR
Reduced bone pain score	20.0 versus 37.3 units; p=NR	2.95 versus 4.37 units; p=0.015

Abbreviations: HR, hazard ratio; NR, not reported.

Reproduced from Semin Oncol, 37(Suppl. 1), Saad and Eastham, Zoledronic acid use in patients with bone metastases from renal cell carcinoma or bladder cancer, S38-S44, Copyright 2010, with permission from Elsevier [2010b].